Does Rallies show 13F holders for MCRB?

Yes. Rallies tracks hedge fund and 13F ownership data for MCRB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MCRB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MCRB. It does not provide personalized investment advice.

MCRB (Seres Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Seres Therapeutics, Inc. (MCRB) is a publicly traded Healthcare sector company. As of May 21, 2026, MCRB trades at $7.79 with a market cap of $73.50M and a P/E ratio of -1.45. MCRB moved +1.88% today. Year to date, MCRB is -49.57%; over the trailing twelve months it is -7.04%. Its 52-week range spans $6.53 to $29.98. Analyst consensus is buy with an average price target of $22.00. Rallies surfaces MCRB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MCRB stock?

Hedge funds tracked by Rallies that own MCRB include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Seres Therapeutics, Inc..

MCRB Key Metrics

Key financial metrics for MCRB
Metric	Value
Price	$7.79
Market Cap	$73.50M
P/E Ratio	-1.45
EPS	$-5.18
Dividend Yield	0.00%
52-Week High	$29.98
52-Week Low	$6.53
Volume	11
Avg Volume	0
Revenue (TTM)	$1.15M
Net Income	$-46.90M
Gross Margin	0.00%

Top Hedge Funds Holding MCRB

Exoduspoint Capital holds 12.74K shares of MCRB, changed -79.03% as of Dec 31, 2025.

Latest MCRB News

Seres Posts $19.9M Q1 Loss, Eyes SER-155 Trial Readout and SER-603 Progress — May 5, 2026
Seres Reveals SER-155 Phase 1b GI Microbiome Shifts Linked to Reduced Bloodstream Infections — Apr 20, 2026
Seres Therapeutics Secures $3.6M CARB-X Award, Plans Phase 1b SER-428 Trial — Apr 9, 2026
Seres Therapeutics Posts $5.7M Net Income, Q2 2026 SER-155 Data Readout On Track — Mar 12, 2026
Seres Appoints Kender as Interim CEO, Seeks Funding Ahead of Q2 2026 SER-155 Readout — Mar 2, 2026

Recent MCRB Insider Trades

Shaff Eric D. sold 259 (~$2.19K) on Feb 15, 2026.
Young Teresa L. sold 75 (~$635.25) on Feb 15, 2026.
DesRosier Thomas sold 78 (~$660.66) on Feb 15, 2026.

MCRB Analyst Consensus

1 analysts cover MCRB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.00.

Common questions about MCRB

Who owns MCRB stock?: Hedge funds tracked by Rallies that own MCRB include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Seres Therapeutics, Inc..
Does Rallies show 13F holders for MCRB?: Yes. Rallies tracks hedge fund and 13F ownership data for MCRB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MCRB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MCRB. It does not provide personalized investment advice.